About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Safety Study of SGN-CD19A for B-Cell Lymphoma | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT01786135

A Safety Study of SGN-CD19A for B-Cell Lymphoma

This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)

Lead sponsor: Seagen Inc.•6 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Seagen Inc.

Age

12 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Pathologically confirmed diagnosis of mantle cell lymphoma, follicular lymphoma Grade 3, diffuse large B-cell lymphoma (DLBCL), including transformed follicular histology, Burkitt lymphoma, or B-lineage lymphoblastic lymphoma
•Relapsed, refractory, or progressive disease following at least 1 prior systemic therapy. Patients with DLBCL or follicular lymphoma Grade 3 must have also received intensive salvage therapy.
•Eastern Cooperative Oncology Group status of 0 or 1
•Measurable disease

Exclusion Criteria

•Allogeneic stem cell transplant (SCT)

Related studies

RECRUITINGPhase 1/2

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more

RECRUITINGPhase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

NCT04195633 · Acute Leukemia, Acute Lymphoblastic Leukemia, and more

RECRUITINGPhase 1

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

NCT04739813 · Lymphoma, Non-Hodgkin Lymphoma, and more

Long-term Follow up Local Registry Study of Kymriah in South Korea

NCT06785818 · B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma

RECRUITINGPhase 1

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

NCT06528301 · Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 19, 2017Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment64

Start dateFeb 2013

Last updatedOct 19, 2017

Condition

Burkitt Lymphoma Lymphoma, Follicular Lymphoma, Large B-Cell, Diffuse Lymphoma, Mantle-Cell Precursor B-cell Lymphoblastic Leukemia-Lymphoma

Locations shown

University of Alabama at Birmingham

Birmingham, Alabama

City of Hope National Medical Center

Duarte, California

Stanford Cancer Center

Stanford, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 19, 2017Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions